James N Ingle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7782919/publications.pdf

Version: 2024-02-01

105	6,078	81743	74018
papers	citations	39 h-index	75 g-index

108	108	108	6846
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	13.9	847
2	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 209-219.	13.9	507
3	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA - Journal of the American Medical Association, 2009, 302, 1429.	3.8	468
4	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	2.3	244
5	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€"A Randomized Controlled Phase III Trial. Journal of Clinical Oncology, 2013, 31, 1398-1404.	0.8	218
6	HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
7	The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor Î± for Degradation in Breast Cancer Cells. Cancer Research, 2009, 69, 1722-1727.	0.4	200
8	Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Research and Treatment, 1999, 54, 117-122.	1.1	130
9	Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032. Journal of Clinical Oncology, 2006, 24, 1052-1056.	0.8	128
10	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptorâ€"Positive Breast Cancer (E-3193,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 3948-3958.	0.8	118
11	A comprehensive analysis of breast cancer microbiota and host gene expression. PLoS ONE, 2017, 12, e0188873.	1.1	111
12	Functional Genetic Polymorphisms in the Aromatase GeneCYP19Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors. Cancer Research, 2010, 70, 319-328.	0.4	102
13	Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemotherapy and Pharmacology, 1987, 20, 219-222.	1.1	98
14	Combination hormonal therapy with tamoxifen plus fluoxymesteroneversus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer, 1991, 67, 886-891.	2.0	95
15	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 1994, 74, 2956-2963.	2.0	93
16	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment, 2006, 99, 295-300.	1.1	89
17	Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer, 1993, 72, 1247-1260.	2.0	87
18	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 167, 89-99.	1.1	74

#	Article	IF	Citations
19	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Research, 2010, 70, 3278-3286.	0.4	63
20	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery, 2013, 3, 812-825.	7.7	61
21	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	61
22	Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer, 1996, 78, 764-772.	2.0	58
23	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3391-3400.	0.8	58
24	Estrogen as therapy for breast cancer. Breast Cancer Research, 2002, 4, 133-6.	2.2	56
25	Estrogen receptors in patients with malignant melanoma. Cancer, 1980, 46, 1785-1786.	2.0	54
26	Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 176, 709-716.	1.1	54
27	ERÎ²1: characterization, prognosis, and evaluation of treatment strategies in ERÎ±-positive and -negative breast cancer. BMC Cancer, 2014, 14, 749.	1.1	53
28	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Research, 2017, 19, 130.	2.2	53
29	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute, 2015, 107, .	3.0	52
30	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
31	Estrogen receptor Î±/Î² isoforms, but not Î²cx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. Journal of Cellular Biochemistry, 2007, 101, 1125-1147.	1.2	49
32	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Molecular Endocrinology, 2013, 27, 657-670.	3.7	49
33	Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1427-1436.	0.8	49
34	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. Npj Breast Cancer, 2020, 6, 4.	2.3	49
35	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Journal of the National Cancer Institute, 2020, 112, 698-707.	3.0	48
36	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research, 2016, 76, 7012-7023.	0.4	47

#	Article	IF	Citations
37	ERÎ²-mediated induction of cystatins results in suppression of TGFÎ² signaling and inhibition of triple-negative breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9580-E9589.	3.3	47
38	Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer, 2008, 112, 695-699.	2.0	41
39	Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer. Cancer, 1981, 47, 240-244.	2.0	39
40	A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinic. Cancer, 1991, 68, 34-39.	2.0	38
41	Endoxifenâ€™s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens. PLoS ONE, 2013, 8, e54613.	1.1	38
42	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids, 2015, 99, 32-38.	0.8	38
43	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, .	3.0	37
44	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clinical Breast Cancer, 2016, 16, 82-86.	1.1	37
45	Additive hormonal therapy in women with advanced breast cancer. Cancer, 1984, 53, 766-777.	2.0	36
46	The lncRNA MIR2052HG regulates ERÎ± levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Research, 2019, 21, 47.	2.2	36
47	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochemical Pharmacology, 2018, 152, 279-292.	2.0	35
48	ERÎ² inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget, 2017, 8, 96506-96521.	0.8	35
49	Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials. Cancer, 1996, 77, 683-690.	2.0	32
50	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1â€“positive Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5628-5637.	3.2	32
51	Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues. Breast Cancer Research and Treatment, 2020, 179, 241-249.	1.1	31
52	Aromatase inhibitors for therapy of advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 113-119.	1.2	29
53	Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer, 1989, 63, 1257-1264.	2.0	27
54	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. Molecular Endocrinology, 2016, 30, 382-398.	3.7	27

#	Article	IF	Citations
55	Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer, 1982, 49, 1353-1354.	2.0	26
56	A phase II study of cis-diamminedichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasms. Head & Neck, 1984, 6, 1020-1023.	0.3	26
57	Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids, 2011, 76, 765-767.	0.8	24
58	Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen. Cancer, 1981, 47, 2549-2551.	2.0	22
59	Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Research, 2017, 19, 95.	2.2	22
60	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERÎ±-positive breast cancer through regulation of BRCA1. PLoS Genetics, 2017, 13, e1007031.	1.5	22
61	Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clinical Cancer Research, 2005, 11, 900s-5s.	3.2	22
62	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 639-647.	1.1	21
63	Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Research and Treatment, 1989, 13, 135-142.	1.1	20
64	Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas. Neurosurgery, 1999, 44, 67-73.	0.6	19
65	Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors. Breast, 2013, 22, S180-S183.	0.9	19
66	Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitorâ€“Treated Patients: CCTG MA.27. Journal of the National Cancer Institute, 2018, 110, 1003-1008.	3.0	19
67	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 557-566.	1.1	19
68	Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. Cancer, 1983, 51, 2020-2023.	2.0	18
69	Pharmacogenomics of endocrine therapy in breast cancer. Journal of Human Genetics, 2013, 58, 306-312.	1.1	18
70	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. Npj Breast Cancer, 2017, 3, 30.	2.3	18
71	TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88â€“Dependent Nuclear Factor-ÎºB Activation: Single-Nucleotide Polymorphismâ€“ and Selective Estrogen Receptor Modulatorâ€“Dependent Modification of Inflammation and Immune Response. Molecular Pharmacology, 2017, 92, 175-184.	1.0	18
72	Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer. Clinical Cancer Research, 2004, 10, 362s-367s.	3.2	18

#	Article	IF	Citations
73	Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. Clinical Cancer Research, 2006, 12, 1031s-1036s.	3.2	17
74	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+Âbreast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Research and Treatment, 2017, 164, 189-199.	1.1	17
75	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. Journal of Clinical Oncology, 2019, 37, 1982-1983.	0.8	17
76	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor Î±. Clinical Cancer Research, 2020, 26, 2986-2996.	3.2	17
77	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Supportive Care in Cancer, 2021, 29, 2509-2517.	1.0	17
78	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight, 2020, 5, .	2.3	16
79	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. Journal of Clinical Oncology, 2015, 33, 503-503.	0.8	16
80	Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial. Menopause, 2020, 27, 693-700.	0.8	15
81	Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 313-319.	1.2	14
82	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research, 2020, 22, 51.	2.2	11
83	Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas. Medical and Pediatric Oncology, 1983, 11, 319-321.	1.0	10
84	Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer, 1989, 63, 1931-1937.	2.0	10
85	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genomeâ€Wide Association Study: Functional Epistatic Interaction Between <scp>SLC</scp>38A7 and <scp>ALPPL</scp>2. Clinical Pharmacology and Therapeutics, 2019, 106, 219-227.	2.3	10
86	TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ÎºB p65: Single Nucleotide Polymorphism and Estrogen Dependence. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 700-710.	1.3	9
87	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFÎºB/p65 signaling in triple negative breast cancer. Npj Breast Cancer, 2022, 8, 20.	2.3	9
88	The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton. PLoS ONE, 2014, 9, e98219.	1.1	8
89	Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clinical Pharmacology and Therapeutics, 2018, 103, 243-252.	2.3	7
90	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). Clinical Cancer Research, 2021, 27, 4696-4699.	3.2	7

#	Article	IF	Citations
91	Skeletal and Uterotrophic Effects of Endoxifen in Female Rats. Endocrinology, 2017, 158, 3354-3368.	1.4	6
92	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor Î±-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. Breast Cancer Research and Treatment, 2019, 175, 567-578.	1.1	6
93	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Earlyâ€Stage Breast Cancer. Clinical Pharmacology and Therapeutics, 2021, 110, 1038-1049.	2.3	5
94	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2014, 106, .	3.0	4
95	Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. Molecular Cancer Therapeutics, 2022, 21, 206-216.	1.9	4
96	Adjuvant endocrine therapy in postmenopausal breast cancer. Clinical Cancer Research, 2003, 9, 480S-5S.	3.2	4
97	Sequencing of Hormonal Therapy in Breast Cancer. Breast Journal, 2002, 8, 332-337.	0.4	3
98	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 3342-3355.	3.2	3
99	Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. Molecular Cancer Research, 2021, 19, 1026-1039.	1.5	2
100	Hormonal Therapy: Current and New Directions. Breast Journal, 2003, 9, S17-S21.	0.4	1
101	Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer. Pharmacogenomics, 2020, 21, 615-625.	0.6	1
102	ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion. Pharmacogenetics and Genomics, 2021, 31, 155-164.	0.7	1
103	Multicultural aspects of breast cancer etiology workshop. , 2000, 88, 1265-1266.		0
104	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenetics and Genomics, 2021, 31, 1-9.	0.7	0
105	Predicting the clinical outcomes and benefit from letrozole after 5Âyears of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. Breast Cancer Research and Treatment, 2021, , 1.	1.1	0